Affordable Access

deepdyve-link
Publisher Website

Four-year comparative effectiveness of bare-metal and everolimus-eluting stents in New York.

Authors
  • Qian, Feng1
  • Zhong, Ye1
  • Hannan, Edward L1
  • 1 Department of Health Policy, Management & Behavior, University at Albany-State University of New York, Albany, New York.
Type
Published Article
Journal
Catheterization and Cardiovascular Interventions
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 15, 2018
Volume
91
Issue
3
Pages
417–424
Identifiers
DOI: 10.1002/ccd.27144
PMID: 28557275
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To study four-year outcomes for patients receiving either bare-metal stents (BMS) or everolimus-eluting stents (EES) and to evaluate the comparative effectiveness of BMS versus EES in six "off-label" and two "high-risk" patient subgroups. BMS and EES (a second generation of drug-eluting stent) are used in contemporary practice to treat coronary artery disease. However, little is known about long-term comparative effectiveness between BMS and EES. Using the New York State (NYS) cardiac registries, statewide hospital discharge data, the National Death Index, and the U.S. Census file, we assessed four-year outcomes of BMS versus EES in patients receiving either BMS or EES from July 2008 through December 2009. The outcomes included all-cause mortality, acute myocardial infarction (AMI), target-lesion PCI (TLPCI), and target-vessel coronary artery bypass graft (TVCABG) surgery for a follow-up period of four years (median follow-up of 3.6 years). We compared 9,290 propensity score matched pairs with further adjustment using Cox proportional hazards regression. Compared with patients receiving BMS, patients receiving EES had a lower rate of four-year mortality (adjusted hazard ratio <AHR>: 0.58, 95% confidence interval <CI>: 0.54-0.63), AMI (AHR: 0.68, 95% CI: 0.61-0.76), TLPCI (AHR: 0.67, 95% CI: 0.60-0.75), and TVCABG (AHR, 0.53, 95% CI: 0.43-0.65). For "off-label" and "high-risk" subgroups, EES was associated with decreased mortality and generally better AMI, TLPCI, and TVCABG outcomes relative to BMS. Compared with BMS use, EES use was associated with better four-year outcomes. © 2017 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times